Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
PLoS One. 2022 Jun 24;17(6):e0270297. doi: 10.1371/journal.pone.0270297. eCollection 2022.
Inflammatory bowel disease is a relapsing chronic gastrointestinal inflammatory disease. Idiopathic pulmonary fibrosis is a rare but serious extraintestinal pulmonary manifestation of inflammatory bowel disease. However, the relationship between these two conditions is unclear. Therefore, this study aims to elucidate this relationship through a systematic review and meta-analysis, focusing on the risk of idiopathic pulmonary fibrosis in patients with inflammatory bowel disease.
The systematic review will be outlined according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols and its extension statement for reporting systematic reviews incorporating network meta-analyses of healthcare interventions: checklist and explanations. Original articles published in any language will be searched in the following databases: PubMed, Web of Science, EMBASE, Google Scholar, and Ovid. Observational studies that reveal an association measure between idiopathic pulmonary fibrosis and inflammatory bowel disease will be included (cross sectional, cohort, and case-control trials). Two independent reviewers will be assigned to evaluate study quality using the Newcastle-Ottawa scale for assessing the quality of non-randomized studies in meta-analyses. Sensitivity analyses will be conducted based on the quality of included studies. All relevant studies will be assessed based on the study type, sample size, inflammatory bowel disease subtype, odds ratio, confidence interval, treatment strategy, and follow-up. The Grading of Recommendations Assessment, Development, and Evaluation approach will be used to rate the quality of the evidence.
The results of this meta-analysis may show that patients with inflammatory bowel disease are at higher risk of developing idiopathic pulmonary fibrosis. This study will be the first meta-analysis to focus on the association between inflammatory bowel disease and idiopathic pulmonary fibrosis. Exploring the relationship between the two conditions may further enhance our understanding of the pathogenesis of inflammatory bowel disease and idiopathic pulmonary fibrosis and promote the development of related research fields.
炎症性肠病是一种反复发作的慢性胃肠道炎症性疾病。特发性肺纤维化是炎症性肠病罕见但严重的肠外肺部表现。然而,这两种疾病之间的关系尚不清楚。因此,本研究旨在通过系统评价和荟萃分析来阐明这种关系,重点关注炎症性肠病患者发生特发性肺纤维化的风险。
系统评价将根据系统评价和荟萃分析报告的首选报告项目和其扩展声明进行概述,该声明用于报告纳入医疗保健干预措施的网络荟萃分析的系统评价:清单和解释。将以任何语言发表的原始文章在以下数据库中进行搜索:PubMed、Web of Science、EMBASE、Google Scholar 和 Ovid。将纳入揭示特发性肺纤维化与炎症性肠病之间关联度量的观察性研究(横断面、队列和病例对照研究)。两名独立的审查员将使用评估荟萃分析中非随机研究质量的纽卡斯尔-渥太华量表来评估研究质量。将根据纳入研究的质量进行敏感性分析。所有相关研究将根据研究类型、样本量、炎症性肠病亚型、优势比、置信区间、治疗策略和随访进行评估。将使用推荐评估、制定和评估方法对证据质量进行评级。
荟萃分析的结果可能表明炎症性肠病患者发生特发性肺纤维化的风险较高。本研究将是首个专注于炎症性肠病和特发性肺纤维化之间关联的荟萃分析。探讨这两种疾病之间的关系可能进一步增强我们对炎症性肠病和特发性肺纤维化发病机制的理解,并促进相关研究领域的发展。